[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HK1219415A1 - 聯苯化合物的結晶游離碱形式 - Google Patents

聯苯化合物的結晶游離碱形式

Info

Publication number
HK1219415A1
HK1219415A1 HK16107421.6A HK16107421A HK1219415A1 HK 1219415 A1 HK1219415 A1 HK 1219415A1 HK 16107421 A HK16107421 A HK 16107421A HK 1219415 A1 HK1219415 A1 HK 1219415A1
Authority
HK
Hong Kong
Prior art keywords
biphenyl compound
crystalline freebase
freebase forms
forms
crystalline
Prior art date
Application number
HK16107421.6A
Other languages
English (en)
Inventor
Grahame Woollam
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42562758&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1219415(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Publication of HK1219415A1 publication Critical patent/HK1219415A1/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • A61K9/124Aerosols; Foams characterised by the propellant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C07D211/64Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having an aryl radical as the second substituent in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK16107421.6A 2009-07-15 2016-06-24 聯苯化合物的結晶游離碱形式 HK1219415A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22580309P 2009-07-15 2009-07-15

Publications (1)

Publication Number Publication Date
HK1219415A1 true HK1219415A1 (zh) 2017-04-07

Family

ID=42562758

Family Applications (2)

Application Number Title Priority Date Filing Date
HK12108950.7A HK1168050A1 (zh) 2009-07-15 2012-09-13 聯苯化合物的結晶游離碱形式
HK16107421.6A HK1219415A1 (zh) 2009-07-15 2016-06-24 聯苯化合物的結晶游離碱形式

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK12108950.7A HK1168050A1 (zh) 2009-07-15 2012-09-13 聯苯化合物的結晶游離碱形式

Country Status (21)

Country Link
US (11) US8541451B2 (zh)
EP (2) EP2453894B1 (zh)
JP (4) JP5651174B2 (zh)
KR (1) KR101742252B1 (zh)
CN (1) CN102470130B (zh)
AU (1) AU2010273514B2 (zh)
BR (1) BR112012000890A2 (zh)
CA (2) CA2765621C (zh)
DK (1) DK2453894T3 (zh)
ES (2) ES2557553T3 (zh)
HK (2) HK1168050A1 (zh)
HR (1) HRP20151344T1 (zh)
HU (1) HUE026414T2 (zh)
IL (1) IL216995A (zh)
MX (1) MX2012000682A (zh)
PL (2) PL2987490T3 (zh)
PT (1) PT2453894E (zh)
SG (2) SG10201407913UA (zh)
SI (1) SI2453894T1 (zh)
SM (1) SMT201600019B (zh)
WO (1) WO2011008809A1 (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
PT2453894E (pt) 2009-07-15 2016-02-02 Theravance Biopharma R&D Ip Llc Forma de base livre cristalina de um composto bifenilo
HUE027140T2 (hu) * 2010-07-13 2016-08-29 Theravance Biopharma R&D Ip Llc Eljárás bifenil-2-ilkarbaminsav elõállítására
PL2958916T3 (pl) * 2013-02-21 2019-01-31 Pfizer Inc. Stałe postacie selektywnego inhibitora CDK4/6
WO2015070366A1 (en) 2013-11-12 2015-05-21 Merck Sharp & Dohme Corp. Aryl linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug
WO2020047225A1 (en) 2018-08-30 2020-03-05 Theravance Biopharma R&D Ip, Llc Methods for treating chronic obstructive pulmonary disease
CN112694434B (zh) * 2020-12-29 2023-06-16 浙江和泽医药科技股份有限公司 一种雷芬那辛新中间体及其活性亲电砌块和雷芬那辛的新制备方法
WO2023104920A1 (en) 2021-12-09 2023-06-15 Medichem, S.A. Crystalline acetone solvate of revefenacin
CN114276290B (zh) * 2021-12-24 2024-05-28 浙江和泽医药科技股份有限公司 一种雷芬那辛无水晶型及其制备方法
CN117180235A (zh) * 2023-09-19 2023-12-08 山东京卫制药有限公司 一种无定型雷芬那辛吸入制剂
CN117263849A (zh) * 2023-09-19 2023-12-22 山东京卫制药有限公司 一种雷芬那辛三水合物晶型及其制备方法
CN117263848A (zh) * 2023-09-19 2023-12-22 山东京卫制药有限公司 一种雷芬那辛的吸入喷雾剂

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2425983C3 (de) * 1973-06-12 1978-09-14 Toyama Chemical Co. Ltd., Tokio Sulfonsäuresalze von Acylcholinen, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzung
BR8007911A (pt) 1979-12-06 1981-06-16 Glaxo Group Ltd Inalador aperfeicoado
ATE23272T1 (de) 1981-07-08 1986-11-15 Draco Ab Pulverinhalator.
DE3682457D1 (de) 1985-07-30 1991-12-19 Glaxo Group Ltd Geraet zur verabreichung von medikamenten an patienten.
US5225183A (en) 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
SK280968B6 (sk) 1990-03-02 2000-10-09 Glaxo Group Limited Balenie medikamentu na použite v inhalačnom prístroji
US6006745A (en) 1990-12-21 1999-12-28 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
US5874063A (en) 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
AU2178392A (en) 1991-06-12 1993-01-12 Minnesota Mining And Manufacturing Company Albuterol sulfate suspension aerosol formulations
US5337740A (en) 1991-08-01 1994-08-16 New England Pharmaceuticals, Inc. Inhalation devices
NZ246421A (en) 1991-12-18 1996-05-28 Minnesota Mining & Mfg Aerosol formulation containing a drug and a propellant and which is substantially free of surfactant
US5239993A (en) 1992-08-26 1993-08-31 Glaxo Inc. Dosage inhalator providing optimized compound inhalation trajectory
US5415162A (en) 1994-01-18 1995-05-16 Glaxo Inc. Multi-dose dry powder inhalation device
WO1995021820A1 (fr) 1994-02-10 1995-08-17 Yamanouchi Pharmaceutical Co., Ltd. Nouveau derive du carbamate et composition correspondante
US5983956A (en) 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
US5637820A (en) * 1995-01-06 1997-06-10 Wittman; Kenneth L. Stringed instrument with on-board tuner
SE9501384D0 (sv) 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
NZ306280A (en) 1995-04-14 1999-07-29 Glaxo Wellcome Inc Metered dose inhaler for salmeterol
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
WO1999016766A1 (fr) 1997-10-01 1999-04-08 Kyowa Hakko Kogyo Co., Ltd. Derives de benzodioxole
AU3328499A (en) 1998-03-14 1999-10-11 Byk Gulden Lomberg Chemische Fabrik Gmbh Phthalazinone pde iii/iv inhibitors
IL139087A0 (en) 1998-04-18 2001-11-25 Glaxo Group Ltd Pharmaceutical aerosol formulation
GB9808802D0 (en) 1998-04-24 1998-06-24 Glaxo Group Ltd Pharmaceutical formulations
SE9804000D0 (sv) 1998-11-23 1998-11-23 Astra Ab New composition of matter
US6693202B1 (en) * 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
WO2000061108A1 (en) 1999-04-14 2000-10-19 Glaxo Group Limited Pharmaceutical aerosol formulation
UA73965C2 (en) 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
DE60220887T2 (de) 2001-03-08 2008-02-28 Glaxo Group Ltd., Greenford Agonisten von beta-adrenorezeptoren
ATE381537T1 (de) 2001-03-22 2008-01-15 Glaxo Group Ltd Formanilid-derivative als beta2-adrenorezeptor- agonisten
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
ES2438985T3 (es) 2001-09-14 2014-01-21 Glaxo Group Limited Formulación de inhalación que comprende derivados de fenetanolamina para el tratamiento de enfermedades respiratorias
WO2003042160A1 (en) 2001-11-13 2003-05-22 Theravance, Inc. Aryl aniline beta-2 adrenergic receptor agonists
PE20050973A1 (es) * 2003-10-29 2005-11-19 Theravance Inc Sales de acido naftalen-1,5-disulfonico de un compuesto de 4-amino-1-(piridilmetil)piperidina como antagonistas de receptores muscarinicos
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
TW200540154A (en) * 2004-06-10 2005-12-16 Theravance Inc Crystalline form of a substituted pyrrolidine compound
WO2006099166A1 (en) * 2005-03-10 2006-09-21 Theravance, Inc. Crystalline forms of a biphenyl compound
TWI372749B (en) 2005-03-10 2012-09-21 Theravance Inc Crystalline forms of a biphenyl compound
US7465870B1 (en) * 2008-03-11 2008-12-16 Homan Randy W Illuminated heart-shaped guitar with strobe lights and a modified bridge
PT2453894E (pt) 2009-07-15 2016-02-02 Theravance Biopharma R&D Ip Llc Forma de base livre cristalina de um composto bifenilo
HUE027140T2 (hu) 2010-07-13 2016-08-29 Theravance Biopharma R&D Ip Llc Eljárás bifenil-2-ilkarbaminsav elõállítására

Also Published As

Publication number Publication date
PL2453894T3 (pl) 2016-04-29
CA2765621C (en) 2018-02-13
US10550081B2 (en) 2020-02-04
US20190248743A1 (en) 2019-08-15
SI2453894T1 (sl) 2016-02-29
HK1168050A1 (zh) 2012-12-21
US10100013B2 (en) 2018-10-16
US8921396B2 (en) 2014-12-30
JP5651174B2 (ja) 2015-01-07
AU2010273514B2 (en) 2015-01-22
WO2011008809A1 (en) 2011-01-20
EP2987490A1 (en) 2016-02-24
KR101742252B1 (ko) 2017-05-31
CN102470130A (zh) 2012-05-23
DK2453894T3 (en) 2016-01-25
IL216995A (en) 2017-10-31
US20220009890A1 (en) 2022-01-13
US20230303492A1 (en) 2023-09-28
JP2016026214A (ja) 2016-02-12
BR112012000890A2 (pt) 2017-10-31
US11649209B2 (en) 2023-05-16
US11858898B2 (en) 2024-01-02
JP2015003929A (ja) 2015-01-08
PL2987490T3 (pl) 2017-12-29
HRP20151344T1 (hr) 2016-01-01
US20220306580A1 (en) 2022-09-29
US8541451B2 (en) 2013-09-24
US20110015163A1 (en) 2011-01-20
US11691948B2 (en) 2023-07-04
US20180186740A1 (en) 2018-07-05
US20200308116A1 (en) 2020-10-01
CA2989129C (en) 2021-03-09
US20170081283A1 (en) 2017-03-23
CA2765621A1 (en) 2011-01-20
PT2453894E (pt) 2016-02-02
IL216995A0 (en) 2012-02-29
ES2639642T3 (es) 2017-10-27
JP2017171692A (ja) 2017-09-28
SG10201407913UA (en) 2015-01-29
EP2453894A1 (en) 2012-05-23
JP2012533550A (ja) 2012-12-27
SMT201600019B (it) 2016-02-25
KR20130027004A (ko) 2013-03-14
US11008289B2 (en) 2021-05-18
US20160143897A1 (en) 2016-05-26
SG178036A1 (en) 2012-03-29
US20150164796A1 (en) 2015-06-18
EP2987490B1 (en) 2017-06-14
US9415041B2 (en) 2016-08-16
EP2453894B1 (en) 2015-11-04
MX2012000682A (es) 2012-02-28
CN102470130B (zh) 2013-09-04
US9765028B2 (en) 2017-09-19
US20130338191A1 (en) 2013-12-19
JP6338505B2 (ja) 2018-06-06
AU2010273514A1 (en) 2012-01-19
ES2557553T3 (es) 2016-01-27
HUE026414T2 (hu) 2016-05-30
US9226896B2 (en) 2016-01-05
CA2989129A1 (en) 2011-01-20

Similar Documents

Publication Publication Date Title
HK1219415A1 (zh) 聯苯化合物的結晶游離碱形式
HK1254977A1 (zh) 索非布韋(sofosbuvir)的結晶形式
ZA201105462B (en) Crystalline insulin-conjugates
SG10201500451TA (en) Crystalline forms of a purine derivative
EP2519525A4 (en) SUBSTITUTED PYRROLO-AMINOPYRIMIDINE COMPOUNDS
ZA201107772B (en) Substituted spiro-amide compounds
EP2519522A4 (en) SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS
EP2423182A4 (en) DIACYLETHYLENEDIAMINE COMPOUND
GB0903759D0 (en) Compound
PT2611779T (pt) Formas cristalinas de um inibidor do fator xa
IL216648A0 (en) Crystalline forms of febuxostat
EP2477628A4 (en) PREPARATION OF CRYSTALLINE FORMS OF DIHYDROPYRAZOLOPYRIMIDINONE
SI2358676T1 (sl) Kristalinična oblika 4-(2-(2-fluorofenoksimetil)fenil)piperidinske spojine
GB0914767D0 (en) Compound
ZA201205726B (en) Substituted naphthalenyl-pyrimidine compounds
EP2505585A4 (en) BIS benzoxazinone CONNECTION
GB0902406D0 (en) Crystalline polymorphic form
GB0909213D0 (en) Compound
ZA201202097B (en) Crystalline forms of substituted pyrazolopyrimidines
ZA201104319B (en) Crystalline forms of a 3-carboxypropyl-aminotetralin compound
EP2487178A4 (en) PYRAZOLOTHIAZOLVERBINDUNG
GB0914883D0 (en) Compound
IL223584A0 (en) Crystalline form of a 3-phenoxymethylpyrrolidine compounds
HUP0800755A2 (en) Crystalline forms of rosiglitazone
EP2502926A4 (en) COMPOUND